Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AstraZeneca PLC ("AstraZeneca PLC" or the "Company") (NASDAQ: AZN) investors of a class action representing investors that bought securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"). AstraZeneca PLC investors have until February 21, 2025 to file a lead plaintiff motion. Investors are encouraged to contact ...

AstraZeneca (AZN) announced that its blockbuster cancer drug, Tagrisso (osimertinib), has been approved in the EU for expanded use in non-small cell lung cancer (NSCLC).The eligible patient population includes adults with locally advanced, unresectable NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 (L858R) substitution mutations whose disease has not progressed during or following platinum-based chemoradiation therapy. The FDA approved this combination in September for a similar indication.The nod i ...

U.K.-based pharmaceutical giant AstraZeneca (AZN 1.41%) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested following fraud-related investigations by the authorities. AstraZeneca expects a sales hit in China, one of its most important international markets.The drugmaker's issues in China have weighed heavily on its performance of late, and its stock is down by ab ...

The most recent trading session ended with Astrazeneca (AZN) standing at $65.35, reflecting a +1.41% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 1.09%. Meanwhile, the Dow experienced a rise of 1.18%, and the technology-dominated Nasdaq saw an increase of 1.03%.Heading into today, shares of the pharmaceutical had gained 0.28% over the past month, outpacing the Medical sector's loss of 2.76% and the S&P 500's loss of 0.71% in that time.Analysts and investors ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.So What: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter category. Here's why they think AstraZeneca (AZN -0.54%), Eli Lilly (LLY 0.86%), and Vertex Pharmaceuticals (VRTX -0.08%) are unstoppable healthcare stocks to buy right now.An unstoppable stock at a great valuationDavid Jagielski (AstraZeneca): If you're buying a top growth stock, you often have to pay a heft ...

SAN FRANCISCO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug importation, and personal information breaches. The probe has caused AstraZeneca American Depositary Shares to decline sharply and raised serious concerns about the company’s business practices in one of its largest markets. Hagens Berman has opened an investigation and urges investors in AstraZeneca American Depos ...

AstraZeneca (AZN) has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with prostate cancer.The CAPItello-281 study evaluated the combination of Truqap, J&J’s (JNJ) Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).Results from the study showed that patients treated with this combin ...

There are plenty of growth stocks trading at obscenely high valuations right now. Part of the reason for that is the current enthusiasm for all things artificial intelligence (AI)-related. Some of those high valuations are because AI has sent some stock prices skyrocketing. However, there are other growth stocks out there being overlooked in the meantime.If you're on the hunt for some deals and are willing to be patient, three overlooked stocks you should consider loading up on right now are AstraZeneca (AZ ...

AstraZeneca (AZN) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its blockbuster cancer drug Tagrisso (osimertinib) for expanded use across a new setting in the non-small cell lung cancer (NSCLC) setting.The CHMP has recommended approving Tagrisso for treating adult patients with locally advanced, unresectable NSCLC with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations, whose disease has not progressed during or followin ...